CSL Biotherapies announced that it has finalized shipment of 11 million doses of Afluria (trivalent, inactivated, “split virus” influenza vaccine [Types A and B]) vaccine for the 2013–2014 season.
Afluria vaccine is indicated for active influenza immunization caused by influenza virus subtypes A and B present in the vaccine. Afluria is indicated for patients aged >5 years old.
Afluria vaccine is available in ten 5mL multi-dose vials and 0.5mL pre-filled syringes.
For more information call (877) 829-6372 or visit Afluria.com.